Frontlight ResearchEarly access
TerminatedNo phase
Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
Key facts
- Who runs it
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 2 people enrolled
- Started
- 17 Feb 2022
- Ended
- 1 Apr 2024
- Type of study
- Interventional
- Treatments tested
- Combined Aerobic and Resistance Exercise Training
- Record updated
- 4 April 2024
- Why it stopped
- Study terminated due to lack of funding
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Histologically confirmed diagnosis of RCC
- Patients being treated with standard of Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent
- Metastatic Measurable disease, as defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with a life expectancy ≥ six months
- Physically able to enroll in the exercise program as determined by the treating medical oncologist and after review by Physical medicine and rehabilitation physicians at Johns Hopkins
- Adequate bone marrow reserve and organ function measured within 28 days prior to administration of study treatment with the following key parameters:
- Hematological:; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; Hemoglobin≥ 9.0 g/dL
- Renal:; Serum Creatinine ≤ 1.5 x the upper limit of normal (ULN) or Calculated Creatinine clearance ≥ 30mL/min
- Hepatic:; Total bilirubin ≤ 1.5 x ULN (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled); Serum Aspartate aminotransferase (AST) and serum Alanine aminotransferase (ALT) ≤ 2.5 x ULN (For patients with documented liver metastases AST and/or ALT ≤ 5 x ULN)
Who cannot take part
- Known underlying uncontrolled brain metastatic lesions requires steroids therapy and/or radiotherapy
- Major surgery within four weeks prior to enrollment
- Radiotherapy for RCC 28 days prior to week 1 day 1
- History of underlying cardiovascular, respiratory, musculoskeletal disease or joint problems that preclude moderate physical activity
- The presence of bone metastasis in the spine, pelvis, and lower limbs
- Currently physically active or moderately active as determined by Leisure Score Index of Godin Leisure-Time Exercise Questionnaire (GSLTPAQ)
Where in United States
- Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, United States
About the trial
What the trial wants to find out
The trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory myokines with the exercise intervention in Interleukin 6 (IL-6), C-reactive Protein (CRP), Leptin, Transforming growth factor beta (TGF-beta), and Interferon (INF) gamma.
The group in the trial
- Supportive CareTreatment being tested
Patients with metastatic renal cell carcinoma (RCC) who are receiving immune-checkpoint inhibitor therapy
Treatment: Combined Aerobic and Resistance Exercise Training
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study of Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
- Record updated
- 4 April 2024